Cargando…

Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials

Background: Immune checkpoint inhibitors (ICIs) have been a significant milestone for the treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs can vary substantially between patients, with disparities in treatment outcomes being potentially driving by changes in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Manning-Bennett, Arkady T, Cervesi, Julie, Bandinelli, Pierre-Alain, Sorich, Michael J, Hopkins, Ashley M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953420/
https://www.ncbi.nlm.nih.gov/pubmed/36831064
http://dx.doi.org/10.3390/biomedicines11020528
_version_ 1784893873472929792
author Manning-Bennett, Arkady T
Cervesi, Julie
Bandinelli, Pierre-Alain
Sorich, Michael J
Hopkins, Ashley M
author_facet Manning-Bennett, Arkady T
Cervesi, Julie
Bandinelli, Pierre-Alain
Sorich, Michael J
Hopkins, Ashley M
author_sort Manning-Bennett, Arkady T
collection PubMed
description Background: Immune checkpoint inhibitors (ICIs) have been a significant milestone for the treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs can vary substantially between patients, with disparities in treatment outcomes being potentially driving by changes in the microbiome. Antibiotics can cause dysbiosis and are hypothesised to impact the efficacy of ICIs Methods: Data were pooled from five randomised clinical control trials, IMpower130, IMpower131, IMpower150, OAK, and POPLAR, assessing atezolizumab in advanced NSCLC. Cox proportional hazard models were used to determine whether antibiotic use within 6-weeks before and after randomisation was associated with progression-free survival (PFS) and overall survival (OS) outcomes, with data further stratified by programmed death ligand-1 (PD-L1) status. Results: Antibiotic use was significantly associated with worsened PFS (hazard ratio (HR) = 1.19 [1.08–1.30], p ≤ 0.001) and OS (HR = 1.27 [1.13–1.42], p ≤ 0.001) in patients treated with atezolizumab and those not treated with atezolizumab (PFS, HR = 1.21 [1.08–1.36] p < 0.001, OS, HR = 1.33 [1.16–1.51] p < 0.001). These associations were relatively consistent in both PD-L1 positive and PD-L1 negative. Conclusions: Antibiotic use within a ±6-week window was significantly associated with worse PFS and OS.
format Online
Article
Text
id pubmed-9953420
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99534202023-02-25 Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials Manning-Bennett, Arkady T Cervesi, Julie Bandinelli, Pierre-Alain Sorich, Michael J Hopkins, Ashley M Biomedicines Communication Background: Immune checkpoint inhibitors (ICIs) have been a significant milestone for the treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs can vary substantially between patients, with disparities in treatment outcomes being potentially driving by changes in the microbiome. Antibiotics can cause dysbiosis and are hypothesised to impact the efficacy of ICIs Methods: Data were pooled from five randomised clinical control trials, IMpower130, IMpower131, IMpower150, OAK, and POPLAR, assessing atezolizumab in advanced NSCLC. Cox proportional hazard models were used to determine whether antibiotic use within 6-weeks before and after randomisation was associated with progression-free survival (PFS) and overall survival (OS) outcomes, with data further stratified by programmed death ligand-1 (PD-L1) status. Results: Antibiotic use was significantly associated with worsened PFS (hazard ratio (HR) = 1.19 [1.08–1.30], p ≤ 0.001) and OS (HR = 1.27 [1.13–1.42], p ≤ 0.001) in patients treated with atezolizumab and those not treated with atezolizumab (PFS, HR = 1.21 [1.08–1.36] p < 0.001, OS, HR = 1.33 [1.16–1.51] p < 0.001). These associations were relatively consistent in both PD-L1 positive and PD-L1 negative. Conclusions: Antibiotic use within a ±6-week window was significantly associated with worse PFS and OS. MDPI 2023-02-11 /pmc/articles/PMC9953420/ /pubmed/36831064 http://dx.doi.org/10.3390/biomedicines11020528 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Manning-Bennett, Arkady T
Cervesi, Julie
Bandinelli, Pierre-Alain
Sorich, Michael J
Hopkins, Ashley M
Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title_full Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title_fullStr Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title_full_unstemmed Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title_short Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
title_sort prognostic associations of concomitant antibiotic use in patients with advanced nsclc treated with atezolizumab: sensitivity analysis of a pooled investigation of five randomised control trials
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953420/
https://www.ncbi.nlm.nih.gov/pubmed/36831064
http://dx.doi.org/10.3390/biomedicines11020528
work_keys_str_mv AT manningbennettarkadyt prognosticassociationsofconcomitantantibioticuseinpatientswithadvancednsclctreatedwithatezolizumabsensitivityanalysisofapooledinvestigationoffiverandomisedcontroltrials
AT cervesijulie prognosticassociationsofconcomitantantibioticuseinpatientswithadvancednsclctreatedwithatezolizumabsensitivityanalysisofapooledinvestigationoffiverandomisedcontroltrials
AT bandinellipierrealain prognosticassociationsofconcomitantantibioticuseinpatientswithadvancednsclctreatedwithatezolizumabsensitivityanalysisofapooledinvestigationoffiverandomisedcontroltrials
AT sorichmichaelj prognosticassociationsofconcomitantantibioticuseinpatientswithadvancednsclctreatedwithatezolizumabsensitivityanalysisofapooledinvestigationoffiverandomisedcontroltrials
AT hopkinsashleym prognosticassociationsofconcomitantantibioticuseinpatientswithadvancednsclctreatedwithatezolizumabsensitivityanalysisofapooledinvestigationoffiverandomisedcontroltrials